AR033828A1 - Benzofenonas y sulfonas como inhibidores de la captacion de glicina y composicion farmaceutica - Google Patents

Benzofenonas y sulfonas como inhibidores de la captacion de glicina y composicion farmaceutica

Info

Publication number
AR033828A1
AR033828A1 ARP010103089A ARP010103089A AR033828A1 AR 033828 A1 AR033828 A1 AR 033828A1 AR P010103089 A ARP010103089 A AR P010103089A AR P010103089 A ARP010103089 A AR P010103089A AR 033828 A1 AR033828 A1 AR 033828A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
amino
hydrogen
inhibitors
Prior art date
Application number
ARP010103089A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR033828A1 publication Critical patent/AR033828A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos de benzofenona y sulfona sustituidos de fórmula (1) en la que el anillo A es fenilo, naftilo, benzotienilo, benzofuranilo o tienilo; o el anillo A es un anillo de arilo o heteroarilo monocíclico que contiene 0-4 heteroátomos y que no contiene átomos de oxígeno de anillo adyacentes; o el anillo A es un anillo de arilo o heteroarilo bicíclico que contiene de 0-5 heteroátomos y que no contiene átomos de oxígeno de anillo adyacentes; Y es C=O ó SO2 y está unido al grupo fenoxi representado en la fórmula (1) en la posición meta o para; X y Z se seleccionan independientemente entre hidrógeno, alquilo C1-6 opcionalmente sustituido con 1 a 7 átomos de flúor, y alcoxi C1-6 opcionalmente sustituido con 1 a 7 átomos de flúor, en los que el número de sustituyentes fluoro en los grupos alquilo C1-6 y alcoxi C1-6 anteriores no puede exceder el número de posiciones en tales grupos que están disponibles para sustitución; o Xy Z se seleccionan independientemente entre carboxi, carboalcoxi C1-6, carboxamido, alquil C1-6-tio, sulfoxilo, sulfonilo, halo, nitro, ciano, amino, alquil C1-6-amino y di[alquil C1-6]amino; y R es hidrógeno o alquilo C1-6, preferiblemente hidrógeno o metilo; o una sal farmacéuticamente aceptable del mismo. Estos presentan actividad como inhibidores del transporte de glicina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas que los contienen y su uso para potenciar la cognición y para el tratamiento de síntomas positivos y negativos de la esquizofrenia y de otras psicosis en los mamíferos, incluyendo los seres humanos.
ARP010103089A 2000-06-30 2001-06-28 Benzofenonas y sulfonas como inhibidores de la captacion de glicina y composicion farmaceutica AR033828A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21569200P 2000-06-30 2000-06-30

Publications (1)

Publication Number Publication Date
AR033828A1 true AR033828A1 (es) 2004-01-07

Family

ID=22803976

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103089A AR033828A1 (es) 2000-06-30 2001-06-28 Benzofenonas y sulfonas como inhibidores de la captacion de glicina y composicion farmaceutica

Country Status (17)

Country Link
US (1) US6506780B2 (es)
EP (1) EP1294677B1 (es)
JP (1) JP3801561B2 (es)
AP (1) AP2001002203A0 (es)
AR (1) AR033828A1 (es)
AT (1) ATE281427T1 (es)
AU (1) AU2001274407A1 (es)
DE (1) DE60106914T2 (es)
DK (1) DK1294677T3 (es)
DO (1) DOP2001000189A (es)
ES (1) ES2230326T3 (es)
PA (1) PA8519901A1 (es)
PE (1) PE20020121A1 (es)
PT (1) PT1294677E (es)
TN (1) TNSN01098A1 (es)
UY (1) UY26802A1 (es)
WO (1) WO2002000602A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566550B2 (en) 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
MXPA05011198A (es) 2003-04-30 2005-12-14 Lundbeck & Co As H Derivados de oxifenilo aromaticos y de sulfanilfenilo aromaticos.
BRPI0413587A (pt) * 2003-08-21 2006-10-17 Lundbeck & Co As H usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença
WO2005100301A1 (en) * 2004-03-31 2005-10-27 Eli Lilly And Company 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors
JP2008527016A (ja) * 2005-01-18 2008-07-24 エフ．ホフマン−ラ ロシュ アーゲー 神経及び神経精神病の疾患の治療のためのグリシントランスポーター１（ＧｌｙＴ−１）阻害剤としての２，５−二置換フェニルメタノン誘導体
DE602006010665D1 (en) 2005-02-07 2010-01-07 Hoffmann La Roche Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1
JP2009535301A (ja) * 2006-04-05 2009-10-01 グラクソ グループ リミテッド グリシントランスポーターを阻害する化合物およびその使用
PL2699543T3 (pl) 2011-04-19 2016-10-31 Nowe modulatory mediowanego receptorem dopaminergicznym i nmda glutaminergicznego przekaźnictwa nerwowego zwojów korowych
IN2014DN07214A (es) 2012-03-01 2015-04-24 Toyota Motor Co Ltd
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1014966T3 (da) * 1996-05-31 2006-12-04 Allelix Neuroscience Inc Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
US6191165B1 (en) * 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders

Also Published As

Publication number Publication date
US20020052401A1 (en) 2002-05-02
DE60106914D1 (de) 2004-12-09
PE20020121A1 (es) 2002-02-16
JP2004501892A (ja) 2004-01-22
PA8519901A1 (es) 2003-06-30
WO2002000602A1 (en) 2002-01-03
EP1294677A1 (en) 2003-03-26
PT1294677E (pt) 2005-01-31
DE60106914T2 (de) 2005-12-08
ES2230326T3 (es) 2005-05-01
TNSN01098A1 (fr) 2005-11-10
JP3801561B2 (ja) 2006-07-26
AP2001002203A0 (en) 2001-09-30
DK1294677T3 (da) 2005-02-07
AU2001274407A1 (en) 2002-01-08
ATE281427T1 (de) 2004-11-15
EP1294677B1 (en) 2004-11-03
UY26802A1 (es) 2002-01-31
DOP2001000189A (es) 2002-03-30
US6506780B2 (en) 2003-01-14

Similar Documents

Publication Publication Date Title
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
FI971312A (fi) Uudet prostaglandiinisyntaasin estäjät
UY24409A1 (es) Inhibidores de la matriz metaloproteasa
AR033828A1 (es) Benzofenonas y sulfonas como inhibidores de la captacion de glicina y composicion farmaceutica
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
DK526188A (da) Benzimidazolin-2-oxo-1-carboxylsyrederivater til anvendelse som 5-ht receptorantagonister i farmaceutiske praeparater
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
AR036598A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1
PA8541001A1 (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
NO870384L (no) Nye fenoliske tioetere som inhibitorer for 5-lipoksygenase
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR039891A1 (es) Compuestos tiofen-amidinas, sus composiciones farmaceuticas y su uso para la preparacion de medicamentos para tratar enfermedades y trastornos mediados por c1s
AR002751A1 (es) Antifungicos de tetrahidrofurano, composiciones farmaceuticas que los contienen y el uso de los compuestos para preparar composiciones farmaceuticas utiles para el tratamiento de infecciones fungicas
DE3881489D1 (de) Peptide mit collagenase hemmender wirkung.
AR072510A1 (es) Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana
AR013157A1 (es) Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion
PE20040768A1 (es) Derivados de arilen-(2-amino-fenil)-carboxamida como inhibidores de la histona desacetilasa (hdac)
SE8107387L (sv) Nya fenylalkylaminer, framstellning derav och anvendning som lekemedel
AR014908A1 (es) Compuestos derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas, su uso, un procedimiento para prepararlos, ycomposiciones farmaceuticas que los contienen
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR021826A1 (es) COMPUESTOS DE 2- FENILPIRAN-4-ONA, PROCESOS PARA PREPARARLOS, USO DE UN COMPUESTO INTERMEDIARIO EN DICHOS, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y USO DE DICHOS COMPUESTOS Y DICHA COMPOSICIoN PARA LA FABRICACIoN DE UN MEDICAMENTO
AR017146A1 (es) Compuestos de 1-(fenil-sustituido)-5-(4-metilsulfonilfenil)pirazol; procedimiento para prepararlos, las composiciones farmaceuticas que los contienen,los agentes inhibidores de la cox-ii que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos.
ES556352A0 (es) Un procedimiento para preparar derivados de 5-oxo-1-imidazolidinacetamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure